Resistance-stabilizing additives for electrolyte

• US 7,807,300 B2
• Filed: 01/31/2006
• Issued: 10/05/2010
• Est. Priority Date: 01/31/2006
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Schmidt, Craig L., Merritt, Donald R.
• Primary Examiner(s): WALKER, KEITH D
• Application Number:
  US11/344,376
• Publication Number:
  US 20070178378A1
• Time in Patent Office: 1,708 Days
• Field of Search: None
• US Class Current: 429/324
• CPC Class Codes: H01M 10/0567 characterised by the additives
• CPC Class Codes: Y02E 60/10 Energy storage using batteries

Abstract

A resistance-stabilizing additive to an electrolyte for a battery cell in an implantable medical device is presented. At least one resistance-stabilizing additive is selected from a group comprising an electron withdrawing group, an aromatic diacid salt, an inorganic salt, an aliphatic organic acid, an aromatic diacid, and an aromatic monoacid.

Claims

1. An electrolyte comprising a base liquid electrolyte composition and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises a compound comprising an electron-withdrawing group that is selected from one of trifluoromethylvinyl acetate and 2,2,2-trifluoroacetamide.

2. An electrolyte comprising a base liquid electrolyte composition and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.

3. An electrolyte comprising:

a base liquid electrolyte composition;

a first resistance-stabilizing additive; and

a second resistance-stabilizing additive combined with the first resistance-stabilizing additive;

wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.

4. The electrolyte of claim 3, wherein second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

5. The electrolyte of claim 4, further comprising:

a third resistance-stabilizing additive, the third resistance-stabilizing additive being different from the first and second resistance-stabilizing additives and comprising at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

6. A method for forming an electrolyte in a battery cell for an implantable medical device, the method comprising:

selecting a first resistance-stabilizing additive;

combining a second resistance-stabilizing additive with the first resistance-stabilizing additive to form a resistance-stabilizing composition; and

combining the resistance-stabilizing composition with a base electrolyte composition for the battery cell;

wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.

7. The method of claim 6, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

8. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises trifluoromethylvinyl acetate, 2,2,2-trifluoroacetamide, or combinations thereof.

9. The battery of claim 8, wherein the resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.

10. An implantable medical device comprising the battery of claim 9.

11. The battery of claim 8, wherein the resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.

12. An implantable medical device comprising the battery of claim 11.

13. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive composition, the additive composition comprising:

a first resistance-stabilizing additive; and

a second resistance-stabilizing additive combined with the first resistance-stabilizing additive;

wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.

14. The battery of claim 13, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

15. An implantable medical device comprising the battery of claim 13.

16. An electrolyte comprising:

a base liquid electrolyte composition;

a first resistance-stabilizing additive; and

a second resistance-stabilizing additive combined with the first resistance-stabilizing additive;

wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.

17. The electrolyte of claim 16, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

18. The electrolyte of claim 17, further comprising:

a third resistance-stabilizing additive, the third resistance-stabilizing additive being different from the first and second resistance-stabilizing additives and comprising at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

19. A method for forming an electrolyte in a battery cell for an implantable medical device, the method comprising:

selecting a first resistance-stabilizing additive;

combining a second resistance-stabilizing additive with the first resistance-stabilizing additive to form a resistance-stabilizing composition; and

combining the resistance-stabilizing composition with a base electrolyte composition for the battery cell;

wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.

20. The method of claim 19, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

21. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive composition, the additive composition comprising:

a first resistance-stabilizing additive; and

a second resistance-stabilizing additive combined with the first resistance-stabilizing additive;

wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.

22. The battery of claim 21, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.

23. An implantable medical device comprising the battery of claim 21.